Top section
Top section
◆ No bitter unrated taste as book grows throughout pricing ◆ Investors keen for household unrated names ◆ Price discovery needed
◆ Stellantis sees stronger demand for shorter leg of €1.25bn dual trancher ◆ RCI Banque prices €750m 5.2 year tightly ◆ Ford finds demand in short end sterling
◆ Big move for AkzoNobel, three months after last trade struggled ◆ Orders peak near nine times the deal size ◆ Deal comes through fair value
Data
More articles
More articles
More articles
-
AstraZeneca, the UK drug company, showed the eager demand for merger and acquisition financings this week when it achieved ultra-tight pricing on a $7bn bond issue to fund its acquisition of US biotech firm Alexion Pharmaceuticals. -
Three unprecedented events this week — a landmark court ruling against Shell and shareholder revolts at Chevron and ExxonMobil — signalled that investors and society at large have rejected the oil industry’s early attempts at joining the low carbon transition and are looking for much more radical action. Oil majors retain good access to capital markets, but the clock is ticking. Jon Hay reports.
-
Europe’s high grade corporate market this week saw one of its busiest days of the year, with a touch over €4.5bn printed from eight tranches on Wednesday, and investors lapped up most of the deals with ease.
-
University College London has issued the first public ESG-labelled bond from the UK’s higher education sector, which it priced flat to fair value. But bankers say that while the demand is there, a lack of supply means deals like this are going to be a rarity.
-
Inside the office of Spondoolicks Emerging Market Bond Fund, May 24.
-
Direct lenders are brandishing low levels of default rates through the coronavirus pandemic as proof of the resilience of the asset class, and are using this track record to attract more investors. But not all funds are equal, and now potential LPs can scrutinise the performance of funds through a full credit cycle and allocate accordingly.
Sub-sections
